Key Points
-
In recent years, the concept of mild cognitive impairment (MCI) has come to represent a transitional stage between normal ageing and very early Alzheimer's disease (AD).
-
Commonly accepted guidelines for MCI have been established — memory complaint, preferably corroborated by an informant, objective memory impairment for age and education, normal general cognition, preserved activities of daily living, and not demented. The precise definitions need to be explicated, but these will probably simply be a refinement of a concept, rather than a major re-definition.
-
The therapies being explored for MCI essentially mirror the therapeutic strategies being developed for AD: acetylcholinesterase inhibitors, antioxidants, anti-inflammatories, glutamate receptor modulators and nootropics. Immunomodulators and secretase inhibitors could also have potential.
-
Several trials of these therapies in MCI are now in progress, which are discussed here. If any of these trials are positive, in that the agent under study is able to slow the progression to the diagnosis of clinically probable AD or to alter the rate of progression of symptoms, this will have a major impact on treatment of many patients.
-
The challenge will remain to further refine the MCI criteria so that treatments can be targeted toward a specific MCI population and not be expanded to all ageing individuals.
Abstract
Most investigators believe that by the time the clinical diagnosis of Alzheimer's disease has been made, sufficient neuronal damage has taken place in the brain to make reversal of the condition unlikely. Prevention would be a more appealing strategy, but the challenges of conducting true primary prevention trials in asymptomatic persons are formidable. The duration and expense of these types of trial make them unappealing. Large numbers of subjects would need to be followed for many years, and without a promising therapeutic agent, this approach would be risky. Hence, the concept of secondary prevention treatment trials involving minimally symptomatic individuals, such as persons with mild cognitive impairment (MCI) — a transitional stage between normal ageing and very early Alzheimer's disease — has evolved and seems more promising. This concept has led to the emergence of a number of clinical trials for MCI, which are discussed here.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Katzman, R. & Fox, P. J. in Epidemiology of Alzheimer's Disease: From Gene to Prevention (eds Mayeux, R. & Christen, Y.) 1–17 (Springer, Heidelberg, 1999).
Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 82, 239–259 (1991).
Cummings, J. L. et al. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44, 2308–2314 (1994).
Brookmeyer, R., Gray, S. & Kawas, C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88, 1337–1342 (1998).
Kukull, W. A. & Ganguli, M. in Neurologic Clinics (ed DeKosky, S.) 923–949 (W. B. Saunders, Philadelphia 2000).
Knopman, D. S. in Mild Cognitive Impairment: Aging to Alzheimer's Disease (ed Petersen, R. C.) 243–258 (Oxford Univ. Press, New York, 2003).
Petersen, R. C. Normal aging, mild cognitive impairment, and early Alzheimer's disease. The Neurologist 1, 326–344 (1995).
Petersen, R. C. Aging, mild cognitive impairment, and Alzheimer's disease. Neurologic Clinics 18, 789–805 (2000).
Petersen, R. C. in Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics (eds Iqbal, K., Sisodia, S. S. & Winblad, B.) 141–151 (J. Wiley & Sons, Chichester, 2001).
McKhann, G. et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939–944 (1984).
Kral, V. A. Senescent forgetfulness: benign and malignant. Can. Med. Assoc. J. 86, 257–260 (1962).
Crook, T. et al. Age-associated memory impairment: Proposed diagnostic criteria and measures of clinical change — Report of a National Institute of Mental Health Work Group. Dev. Neuropsychol. 2, 261–276 (1986).
Levy, R. Aging-associated cognitive decline. Int. Psychogeriatr. 6, 63–68 (1994).
Graham, J. E. et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 349, 1793–1796 (1997).
Larrieu, S. et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 59, 1594–1599 (2002). This population-based study corroborated other clinical-based studies with respect to the outcome of MCI. However, it also raised questions concerning the lack of stability of the diagnosis of MCI.
Bennett, D. A. et al. Natural history of mild cognitive impairment in older persons. Neurology 59, 198–205 (2002). MCI was shown to produce an increased risk for individuals to progress to AD and for death. This study emphasized the importance of identifying MCI early and pursuing potential treatments.
Unverzagt, F. W. et al. Prevalence of cognitive impairment: data from the Indianapolis Study of Health and Aging. Neurology 57, 1655–1662 (2001). Cognitive impairment in African-Americans was found to be quite common in the community and was a risk factor for dementia.
Ritchie, K., Artero, S. & Touchon, J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology 56, 37–42 (2000).
Flicker, C., Ferris, S. H. & Reisberg, B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology 41, 1006–1009 (1991). The term 'MCI' was introduced into the literature in this early study using the Global Deterioration Scale as a means of classifying subjects.
Daly, E. et al. Predicting conversion to Alzheimer disease using standardized clinical information. Arch. Neurol. 57, 675–680 (2000). This study from Boston documented the importance of the clinical history in establishing the diagnosis of MCI or questionable dementia.
Bowen, J. et al. Progression to dementia in patients with isolated memory loss. Lancet 349, 763–765 (1997).
Welsh, K., Butters, N., Hughes, J., Mohs, R. & Heyman, A. Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch. Neurol. 48, 278–281 (1991).
Petersen, R. C. et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1133–1142 (2001). The American Academy of Neurology performed an evidence-based medicine review of the literature on MCI and concluded that MCI is important for clinicians to recognize since these subjects are at an increased risk of developing AD.
Petersen, R. C. in Mild Cognitive Impairment: Aging to Alzheimer's Disease (ed Petersen, R. C.) 229–242 (Oxford Univ. Press, New York, 2003).
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. (American Psychiatric Association, Washington, DC, 1994).
Hughes, C. P., Berg, L., Danzinger, W. L., Coben, L. A., Martin, R. L. A new clinical scale for the staging of dementia. Brit. J. Psychiat. 140, 566–572 (1982).
Morris, J. C. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412–2414 (1993).
Reisberg, B., Ferris, S. H., de Leon, M. J. & Crook, T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am. J. Psychiatry 139, 1136–1139 (1982).
Petersen, R. C. Mild cognitive impairment or questionable dementia? Arch. Neurol. 57, 643–644 (2000).
Petersen, R. C. et al. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303–308 (1999). This Mayo Clinic study outlined these investigators' experience with MCI in the community. This study documented clinical criteria and outcomes for these subjects and provided baseline data for clinical trials.
Petersen, R. C. in Mild Cognitive Impairment: Aging to Alzheimer's Disease (ed Petersen, R. C.) 1–14 (Oxford Univ. Press, New York, 2003). This is the first book on MCI to review the current status of the concept. This chapter gives a theoretical framework from which to interpret the literature on MCI.
Petersen, R. C. et al. Current concepts in mild cognitive impairment. Arch. Neurol. 58, 1985–1992 (2001).
Lopez, O. L. et al. Prevalence and classification of mild cognitive impairment in a population study. Neurobiol. Aging 23, S138 (2002).
Davis, K. L. et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281, 1401–1406 (1999).
Mufson, E. J. et al. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J. Comp. Neurol. 427, 19–30 (2000).
Doody, R. S. et al. Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1154–1166 (2001).
Reisberg, B. et al. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348, 1333–1341 (2003).
Hardy, J. & Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12, 383–388 (1991).
Hardy, J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20, 154–159 (1997).
Younkin, S. G. Processing of the Alzheimer's disease A β4 amyloid protein precursor (APP). Brain Pathol. 1, 253–262 (1991).
Selkoe, D. J. in Neurologic Clinics (ed DeKosky, S.) 903–921 (W. B. Saunders, Philadelphia, 2000).
Vassar, R. et al. β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735–741 (1999).
Hussain, I. et al. Identification of a novel aspartic protease (Asp 2) as β-secretase. Mol. Cell. Neurosci. 14, 419–427 (1999).
Sinha, S. et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402, 537–540 (1999).
Yan, R. et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402, 533–537 (1999).
Schenk, D. Alzheimer's disease. A partner for presenilin. Nature 407, 34–35 (2000).
Weiner, H. L. et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzhiemer's disease. Ann. Neurol. 48, 567–579 (2000).
Hock, C. et al. Generation of antibodies specific for beta-amyloid by vaccination of patient with Alzheimer disease. Nature Med. 8, 1270–1275 (2002).
McLaurin, J. et al. Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis. Nature Med. 8, 1263–1269 (2002).
Hock, C. et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547–554 (2003).
Breitner, J. Inflammatory processes and anti-inflammatory drugs in Alzheimer's disease: a current appraisal. Neurobiol. Aging 17, 789–794 (1996).
Pasinetti, G. M. & Aisen, P. S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 87, 319–324 (1998).
Aisen, P. S. & Davis, K. L. Inflammatory mechanisms in Alzheimer's disease: Implications for therapy. Am. J. Psychiatry 151, 1105–1113 (1994).
Aisen, P. S. et al. A randomized controlled trial of prednisone in Alzheimer's disease: Alzheimer's Disease Cooperative Study. Neurology 54, 588–593 (2000).
Weggen, S. et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212–216 (2001).
Aisen, P. S. et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289, 2865–2867 (2003).
Lines, C. R., McCarroll, K. A., Lipton, R. B. & Block, G. A. Telephone screening for amnestic mild cognitive impairment. Neurology 60, 261–266 (2003).
Tang, M. X. et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348, 429–432 (1996).
Waring, S. C. et al. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology 52, 965–970 (1999).
Mulnard, R. A. et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 283, 1007–1015 (2000).
Shumaker, S. A. et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. JAMA 289, 2651–2662 (2003).
Sano, M. et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment of Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 336, 1216–1222 (1997).
Lynch, G. et al. Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp. Neurol. 145, 89–92 (1997).
Johnson, S. A. & Simmon, V. F. Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment. J. Mol. Neurosci. 19, 197–200 (2002).
Waegemans, T. et al. Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement. Geriatr. Cogn. Disord. 13, 217–224 (2002).
Lockhart, B. P. & Lestage, P. J. Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which? Exp. Gerontol. 38, 119–128 (2003).
Geda, Y. E. & Petersen, R. C. in Alzheimer's Disease and Related Disorders Annual 2001. (eds Gauthier, S. & Cummings, J. L.) 69–83 (Martin Dunitz, London, 2001).
Petersen, R. C. Mild cognitive impairment. Neurobiol. Aging 23, S145 (2002).
Brandt, J., Spencer, M. & Folstein, M. The telephone interview for cognitive status. Neuropsychiatry Neuropsychol. Behav. Neurol. 1, 111–117 (1988).
Folstein, M. F., Folstein, S. E. & McHugh, P. R. 'Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189–198 (1975).
Wechsler, D. A. Wechsler Memory Scale — Revised (Psychological Corporation, New York, 1987).
Jack, C. R. Jr. et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 49, 786–794 (1997).
Jack, C. R. Jr. et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52, 1397–1403 (1999). Neuroimaging has become an important aspect of research on MCI and this study documents the utility of volumetric measurement of the hippocampal formation in predicting the outcome of MCI.
Jack, C. R. Jr. in Mild Cognitive Impairment: Aging to Alzheimer's Disease (ed Petersen, R. C.) 105–132 (Oxford Univ. Press, New York, 2003).
Fox, N. C., Warrington, E. K., Seiffer, A. L., Agnew, S. K. & Rossor, M. N. Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study. Brain 121, 1631–1639 (1998).
Rosen, W. G., Mohs, R. C. & Davis, K. L. A new rating scale for Alzheimer's disease. Am. J. Psychiatry 141, 1356–1364 (1984).
Salloway, S., Kumar, D., Ieni, J., Goldman, R. & Richardson, S. Benefits of donepezil treatment in patients with mild cognitive impairment. Neurology 60S1, A411–A412 (2003).
Kokmen, E., Smith, G. E., Petersen, R. C., Tangalos, E., Ivnik, R. J. The short test of mental status: Correlations with standardized psychometric testing. Arch. Neurol. 48, 725–728 (1991).
Acknowledgements
I would like to thank Ms. Donna Asleson for her expert secretarial assistance with the manuscript. This work was supported by grants from the National Institute on Aging (AG 06786, AG 1657, AG 10483).
Author information
Authors and Affiliations
Related links
Related links
FURTHER INFORMATION
Encyclopedia of Life Sciences
Glossary
- NOOTROPIC
-
Compound designed to improve cognition.
Rights and permissions
About this article
Cite this article
Petersen, R. Mild cognitive impairment clinical trials. Nat Rev Drug Discov 2, 646–653 (2003). https://doi.org/10.1038/nrd1155
Issue Date:
DOI: https://doi.org/10.1038/nrd1155
This article is cited by
-
Differential Diagnoses and Clinical Implications of Medication Nonadherence in Older Patients with Chronic Kidney Disease: A Review
Drugs & Aging (2020)
-
Impaired Functional Criticality of Human Brain during Alzheimer’s Disease Progression
Scientific Reports (2018)
-
Targeted metabolomics reveals altered oxylipin profiles in plasma of mild cognitive impairment patients
Metabolomics (2017)
-
Galantamine
ChemTexts (2017)
-
Dysexecutive syndrome in amnesic mild cognitive impairment: a multicenter study
BMC Neurology (2016)